From JCOIN:
In a new article published in JAMA, JCOIN researchers found that 27.6% of United States jails offer all three FDA-approved medications for opioid use disorder (MOUD)—methadone, buprenorphine, and naltrexone—to select individuals, and 16.9% offer them to anyone with opioid use disorder (OUD). Providing MOUD during incarceration creates an opportunity to initiate care and supports continuity of treatment as individuals transition back into the community (Cates & Brown, 2023). The study authors reported that even within jails that offer some form of MOUD, many people do not receive recommended care while detained due to policy, regulatory, financing, staffing, and/or educational barriers.
“Jails are a key touchpoint for engaging people with opioid use disorder in treatment services,” says Dr. Lori J. Ducharme, former health scientist administrator at the National Institute on Drug Abuse. “Availability of MOUD in jails can provide an opportunity for individuals to initiate OUD treatment and ensure continuity of care as people transition between detention and the community. Making the full array of MOUD available respects patients’ needs and preferences, and can ease transitions to available community-based services.”
This study involved fielding the JCOIN National Survey of Substance Use Services in U.S. Jails, a two-part survey using a nationally representative sample. Part 1 was administered to 1,028 jails between June 2022 and April 2023, examining the general availability of MOUD in jails within the past 12 months. The findings were published in September 2024 (Flanagan Balawajder et al., 2024), with a summary. Continue reading >>>
|
|
|
|
